Specialty Pharmacy

Larry Buie, PharmD, BCOP, FASHP, outgoing president of the Hematology/Oncology Pharmacy Association (HOPA), shares some details of HOPA’s upcoming 2022 annual conference in Boston and provides an overview of his term as HOPA’s president.

Osimertinib (Tagrisso; AstraZeneca) is FDA approved for 3 unique cancer indications.

Pluvicto is indicated for the treatment of adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who were previously administered other anticancer therapies.

Bevacizumab (Avastin) is a vascular endothelial growth factor inhibitor indicated several cancer types.

Analysis of the trial show that intensifying the chemotherapy regimen allowed for elimination of radiation in 90% of pediatric patients with T-cell acute lymphoblastic leukemia.

Sandostatin treats severe diarrhea and flushing associated with metastatic carcinoid tumors, as well as treatment of acromegaly.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the understanding of malignant lymphomas’ pathobiology and relationship with the immune system evolved during her clinical and investigational research into the subject.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the field of hematopathology has changed over the last decade.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses next steps following the results of the phase 2 trial assessing niraparib on the treatment of patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.

Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the advantages of including pharmacy staff as part of the care team when payer or drug availability challenges arise.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses her American Society for Investigative Pathology Gold-Headed Cane Award lecture at the Experimental Biology 2022 conference on the classification of lymphoma in the modern era.

As the profession moves more toward the internet, it is helpful to know how to best use the various platforms.

Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

Ideally, these contracts help address criticism of the 340B program, improve patient outcomes, and increase compliance.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the endpoints of the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Relatlimab plus nivolumab (Opdualag) shows improved progression-free survival compared with nivolumab monotherapy in patients with unresectable or metastatic melanoma.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses how patients were selected for the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses how SGO shapes and guides the direction of medical researchers and health care professionals in the gynecologic oncology field.

Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.

Use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer resulted in meaningful anti-tumor activity, consistent safety, and favorable tolerability.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the design of the phase 2 trial assessing niraparib in patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the future of the pharmacist on the gynecologic oncology patient care team.

Black women are at an increased risk of dying from cancer of any type compared to White women, but gynecologic cancers have some of the widest survival gaps.

Hormone replacement therapy can improve quality of life without necessarily increasing the risk of recurrence.

Although poorer prognoses are common for all patients with advanced and recurrent endometrial cancers, minority populations are disproportionately affected with higher rates of mortality.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the role of the pharmacist in gynecologic oncology patient care and treatment.